Life Sciences on the Lake
You talked and we listened! ATC is committed to supporting your focus on building the Life Sciences community in an alternative social atmosphere (translated: no more chicken dinners!). Help us help you build your community! Bring yourself, your teams, your potential hires, and your sombreros for some informal Austin-Life Sciences-Team building on Lady Bird Lake (spouses and significant others welcome). Members (hint, hint) get special pricing and besides, where else can you get food, drinks AND an evening of entertainment for $55?!
Register here
When: Thursday, June 20
Where: The boat will leave from the Capital Cruise dock at the Hyatt Regency Hotel at 6:00 pm
Past Events
HR Best Practices
Moderator:
Ana Ward, Senior VP and General Counsel, Asuragen
Speakers:
Edwin Chien, HR Manager, Luminex
Miranda Ippolito, Senior Manager, Talent Acquisition, Life Technologies
Gail Page, Managing Partner, Vineyard Investment Advisors
Where: The Driskill Hotel (map)
When: Wednesday, April 10, 5:30-7:30 p.m.
For many young and expanding mid-size life sciences companies, it is sometimes unclear how to best manage development of company culture and human capital. The leader of a life sciences company faces the challenge of nurturing and encouraging changes and innovation within the team from science to commerce-related duties. How should your company leverage HR to develop expectations and skills for global collaboration and training to enhance performance and innovation?
Thank you to our program sponsors:
See the full Life Sciences calendar here.
Alternative Financing
Thank you for joining ATC and Life Sciences leaders at the Driskill Hotel on Tuesday, January 22 for dinner and discussion of Alternative Financing, led by CEO of Xeris Pharmaceuticals, John Kinzell, CEO of Savara Pharmaceuticals, Rob Neville and CEO of Mirna Therapeutics, Paul Lammers.
Please follow the links below to gain access to the presentation:
Funding topics included:
- NIH
- Angel Investments
- Texas Funding
- Venture Capitalists
John Kinzell, Ph.D., has 25 years of operations and product development experience in the biotechnology and chemical industries. Most recently, he was the Global Head of Regulatory Affairs at Arysta LifeScience, and prior to that, Head of Regulatory Affairs at Arysta LifeScience’s US business unit where he managed all pre-registration testing programs and regulatory activities. In 1998, John founded Optime Therapeutics, a Bay Area drug delivery company. As CEO, he raised over $8M and oversaw the development of the company’s lead compound through a Phase 2a clinical trial for osteoarthritis. In 1994, he was one of four senior managers recruited by Tomen Corporation (Japan) to start an international agrochemical division with products acquired from Chevron Chemical.In 1983, he co-founded Southwest BioLabs, a contract research and consulting company in New Mexico. He was previously a director of the California Kidney Cancer Foundation. Currently, he is an advisor to Security Research Associates’ life science investment banking practice and a member of BayBio’s Government Relations Committee.
Rob Neville is currently CEO of Austin-based Savara. Savara is entering Phase II clinical trials for AeroVanc, the first inhaled antibiotic being developed to treat the increasing number of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) infections in patients with cystic fibrosis (CF). As CEO, Rob has raised ~$20M for Savara from a number of angel networks including the Central Texas Angel Network and the Northern Texas Angel Network, The Keiretsu Forum, the Tech Coast Angels, and The Aggie Network. Additional lightly-dilutive funds have been raised from the Emerging Technology Fund, the NIH, and various foundations. Prior to Savara, Rob was founder and CEO of Evity, Inc., which he sold to BMC in 2000 for $100M. Evity was funded via a single angel round of investment.
Dr. Paul Lammers is President and CEO of Mirna Therapeutics. The company’s recent financial round of $34.5 million, is Mirna’s first institutional financing, increases to nearly $50 million the investment capital the company has received since launching. Prior to joining Mirna Therapeutics, Dr. Lammers was most recently president of Repros Therapeutics. Dr. Lammers served for 6 years as the Chief Medical Officer for EMD Serono Inc. and began his career with Organon spending 8 years in the commercial and clinical operations in Europe and the US. He also served 4 years as Senior Vice President of clinical and regulatory affairs at Zonagen. Dr. Lammers obtained his Medical Degree and Masters of Science degree from the Catholic University in Nijmegen, The Netherlands, and moved with his family to the US in 1992.
Thanks to our program sponsors:
Managing Clinical Trials Outside of the U.S.
Life Sciences CEO Forum
Watch our Panelists live: “Managing Clinical Trials Outside of the U.S.”
Join the virtual discussion centered on the strategic benefits of managing therapeutics and medical device clinical trials in the EU and alternative markets: Brazil, Russia, China & India, regulation challenges, and clinical data predictions for medical device and therapeutic clinical trials.
Speakers Include:
René van de Zande, President & CEO, Emergo Group
John Potthoff, President & CEO, Theorem
Paul Lammers, President & CEO, Mirna Therapeutics
James Oury, Oury Clark (live from London)
Click HERE for the Presentation
Watch on Youtube:
You will either be able to watch the panel discussion live on YouTube by searching the following name, “Managing Clinical Trials Outside of the US”), or by visiting the following URL and watching directly on the Austin Technology Council’s homepage: https://plus.google.com/117203002236982290521/posts
Thank you to our program sponsors:
Thank you to:
email: 
Cross Systems Consulting